OBJECTIVES: Survey was conducted to assess state of viral hepatitis care in Central and Eastern Europe (CEE). METHODS: Representatives of 16 CEE countries completed on-line survey in April-May 2017 that collected information on basic epidemiology and availability of key services for HCV and HBV infections. Sources of information provided ranged from national surveillance data to expert opinion. RESULTS: The burden of viral hepatitis varied between countries, ranging from 6,500 to 2 million for HCV and from 10,000 to 3 million for HBV. Access to routine HCV RNA testing and genotyping was reported by 11 and 9 countries, respectively. HCV resistance testing was available in 7 countries. Direct acting antivirals (DAAs) were available in 13 countries, most frequently Sofosbuvir and Ledipasvir/Sofosbuvir (12 countries apiece) and Ombitasvir/Paritaprevir/Dasabuvir (9 countries). HBV DNA testing and HBV genotyping were routinely available in 10 and 7 countries, respectively. Eleven countries reported available treatment with Tenofovir. CONCLUSIONS: There are gaps in viral hepatitis care in CEE. Despite the availability of registered modern drugs for HCV and HBV, the access to treatment is limited. Ensuring quality health care is essential to reduce the epidemic and achieve the WHO's goal of eliminating viral hepatitis as a major public health challenge.

Faculty of Medicine Belgrade University Clinic of Infectious Diseases Belgrade Serbia

Hospital for Infectious Diseases Medical University of Warsaw Warsaw Poland

Infectious Diseases AIDS and Clinical Immunology Research Centre Tbilisi Georgia

National Centre of Infectious and Parasitic Diseases Sofia Bulgaria

Nicolae Testemitanu State University of Medicine and Pharmacy Chisinau Republic of Moldova

University Medical Centre Ljubljana Ljubljana Slovenia

000      

00000naa a2200000 a 4500

001      

bmc19039692

003      

CZ-PrNML

005      

20191113105529.0

007      

ta

008      

191111s2019 xr d f 000 0|eng||

009      

AR

024    7_

$a 10.21101/cejph.a5486 $2 doi

035    __

$a (PubMed)31580556

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xr

100    1_

$a Chkhartishvili, Nikoloz $u Infectious Diseases, AIDS and Clinical Immunology Research Centre, Tbilisi, Georgia

245    10

$a State of viral hepatitis care in 16 countries of Central and Eastern European Region / $c N. Chkhartishvili, T. Holban, J. Simonović Babić, I. Alexiev, M. Matičič, J. Kowalska, A. Horban, ECEE Network Group

520    9_

$a OBJECTIVES: Survey was conducted to assess state of viral hepatitis care in Central and Eastern Europe (CEE). METHODS: Representatives of 16 CEE countries completed on-line survey in April-May 2017 that collected information on basic epidemiology and availability of key services for HCV and HBV infections. Sources of information provided ranged from national surveillance data to expert opinion. RESULTS: The burden of viral hepatitis varied between countries, ranging from 6,500 to 2 million for HCV and from 10,000 to 3 million for HBV. Access to routine HCV RNA testing and genotyping was reported by 11 and 9 countries, respectively. HCV resistance testing was available in 7 countries. Direct acting antivirals (DAAs) were available in 13 countries, most frequently Sofosbuvir and Ledipasvir/Sofosbuvir (12 countries apiece) and Ombitasvir/Paritaprevir/Dasabuvir (9 countries). HBV DNA testing and HBV genotyping were routinely available in 10 and 7 countries, respectively. Eleven countries reported available treatment with Tenofovir. CONCLUSIONS: There are gaps in viral hepatitis care in CEE. Despite the availability of registered modern drugs for HCV and HBV, the access to treatment is limited. Ensuring quality health care is essential to reduce the epidemic and achieve the WHO's goal of eliminating viral hepatitis as a major public health challenge.

650    12

$a antivirové látky $x farmakologie $7 D000998

650    _2

$a hepatitida B $x epidemiologie $x prevence a kontrola $7 D006509

650    12

$a hepatitida C $x epidemiologie $x prevence a kontrola $7 D006526

650    _2

$a lidé $7 D006801

651    _2

$a Evropa $x epidemiologie $7 D005060

651    _2

$a východní Evropa $7 D005061

655    _2

$a časopisecké články $7 D016428

700    1_

$a Holban, Tiberiu $u Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

700    1_

$a Simonović Babić, Jasmina $u Faculty of Medicine Belgrade University, Clinic of Infectious Diseases, Belgrade, Serbia

700    1_

$a Alexiev, Ivailo $u National Centre of Infectious and Parasitic Diseases, Sofia, Bulgaria

700    1_

$a Matičič, Mojca $u University Medical Centre Ljubljana, Ljubljana, Slovenia

700    1_

$a Kowalska, Justyna $u Hospital for Infectious Diseases, Medical University of Warsaw, Warsaw, Poland

700    1_

$a Horban, Andrzej $u Hospital for Infectious Diseases, Medical University of Warsaw, Warsaw, Poland

710    2_

$a ECEE Network Group

773    0_

$w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 27, č. 3 (2019), s. 212-216

856    41

$u https://pubmed.ncbi.nlm.nih.gov/31580556 $y Pubmed

910    __

$a ABA008 $b B 1829 $c 562 $y p $z 0

990    __

$a 20191111 $b ABA008

991    __

$a 20191112100443 $b ABA008

999    __

$a ok $b bmc $g 1464350 $s 1078286

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2019 $b 27 $c 3 $d 212-216 $e - $i 1210-7778 $m Central European Journal of Public Health $n Cent. Eur. J. Public Health $x MED00001083

LZP    __

$b NLK118 $a Pubmed-20191111